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PharmacokineticsAbstract A new and simple HPLC assay method was developed and validated for the determina-
tion of etamsylate in human plasma. After protein precipitation with 6% perchloric acid, satisfac-
tory separation was achieved on a HyPURITY C18 column (250 mm · 4.6 mm, 5 lm) using a
mobile phase comprising 20 mM sodium dihydrogen phosphate-2 hydrate (pH was adjusted to
3.5 by phosphoric acid) and acetonitrile at a ratio of 95:5 v/v. The elution was isocratic at ambient
temperature with a ﬂow rate of 0.75 ml/min. Allopurinol was used as internal standard. The cali-
bration curve was linear over the range from 0.25 to 20 lg/ml (r2 = 0.999). The limit of quantiﬁca-
tion for etamsylate in plasma was 0.25 lg/ml. The within day coefﬁcient of variance (%CV) ranged
from 3.9% to 10.2%, whereas the between-day %CV ranged from 3.1% to 8.7%. The assay method
has been successfully used to estimate the pharmacokinetics of etamsylate after oral administration
of a 500 mg tablet under fasting conditions to 24 healthy Egyptian human male volunteers. Various
pharmacokinetic parameters including AUC0–t, AUC0–1, Cmax, Tmax, t1/2, MRT, Cl/F, and Vd/F
were determined from plasma concentration–time proﬁle of etamsylate.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Etamsylate is an orally administered hemostatic drug. It is
used in the treatment of capillary hemorrhage, hematemesis,
hemoptysis, malena, hematuria, epistaxis, menorrhagia and
post partum hemorrhage (Sweetmann, 2002). It works by
increasing capillary endothelial resistance and promoting
platelet adhesion. It reduces capillary bleeding in the presence
of normal number of platelets. In addition, etamsylate is
effective in the prevention and treatment of pre-, per-, or
Figure 1 Chemical structure of etamsylate.
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and in those affecting highly vascularized tissues such as
E.N.T., gynecology, obstetrics, urology, ophthalmology, plas-
tic and reconstructive surgery (Symes, 1975; Harrison and
Campbell, 1976). Etamsylate is chemically 2,5-dihydroxy ben-
zene sulfonic acid with N-ethylethanamine (Fig. 1). The molec-
ular formula of etamsylate is C10H17NO5S and the molecular
weight is 263.33 g/mol. It is completely soluble in water, meth-
anol, and ethanol but partially soluble in methylene chloride
(Merck Index, 1989).
Several analytical methods were developed for the assay
of etamsylate in pharmaceutical formulations. These methods
include; spectrophotometry (Xu et al., 1994; El-Shabrawy
et al., 2004; El-Enany et al., 2007; Goyal and Singhvi,
2008; Zhang et al., 2010), HPTLC (Jaiswal et al., 2005a,b),
HPLC (Ma and Liu, 1984; Xu et al., 1994; El-Shabrawy
et al., 2004; Kaul et al., 2005; Jaiswal et al., 2005a,b; El-
Enany et al., 2007; Nagaraju et al., 2008; Goyal and Singhvi,
2008; Zhang et al., 2010; Chandrshekhara et al., 2010; Vam-
shikrishna and Sathish Kumar, 2011), electrochemical meth-
ods (Wang et al., 2001,2005; Wang and Xu, 2007; Zhang and
Wang, 2005), chemiluminescence (Zhang et al., 1998; Yang
et al., 2002; Li et al., 2002; Du et al., 2002) and capillary
electrophoresis (Li and Ju, 2006). To the best of our knowl-
edge, no HPLC method has been yet reported for the deter-
mination of etamsylate in human plasma. Also, no
pharmacokinetic studies have been published before. Owing
to its great therapeutical importance and widespread use,
studying the pharmacokinetic parameters of the drug is a
prerequisite for the current study. Therefore, a new and sim-
ple validated HPLC assay method for the determination of
etamsylate in human plasma was developed.
2. Materials and methods
2.1. Chemicals
Etamsylate and allopurinol were purchased from Sigma–Al-
drich Co., St. Louis, MO, USA; Dicynone tablets
(500 mg Etamsylate) were purchased from OM Pharma,
Geneva, Switzerland; All chemicals and reagents used were
of LC grade and were purchased from Merck Chemicals,
Germany; Milli-Q grade (Millipore, Bedford, MA, USA)
water was used in all cases. Serum was prepared from nor-
mal human blood, procured freshly from healthy volunteers
through a local blood bank and pooled for spiking and using
as control blank samples.
2.2. Instruments
The analysis of etamsylate was performed in HPLC system
equipped with a variable-wavelength ultraviolet (UV) detector
and an automatic injector (LC-10 VP, Shimadzu ScientiﬁcInstrument, Kyoto, Japan). Data analysis program Class-VP
(Shimadzu Scientiﬁc Instruments, Kyoto, Japan) was used
for data acquisition and processing. Other instruments used
in this study include Bath sonicator (UltraSonik 57X, Elms-
ford, USA); Balance (Sartorius, Germany); Magnetic stirrer
(Stuart, Stone, Staffordshine, UK); Centrifuge (Hettich, Ger-
many); pH meter (520 laboratory instrument, USA); Vortex
tube mixer (Heidolph, Germany); Brand auto micro-pipettes
(Labnet, USA); and micro liter syringes from Hamilton (Bon-
aduz, Switzerland).
2.3. HPLC system and operating conditions
Separation was accomplished with a HyPURITY C18 column
(250 mm · 4.6 mm, 5 lm; Thermo Fisher Scientiﬁc, Waltham,
MA). The mobile phase comprised 20 mM sodium dihydrogen
phosphate-2 hydrate (pH was adjusted to 3.5 by phosphoric
acid) and acetonitrile at a ratio of 95:5 v/v; the elution was iso-
cratic at ambient temperature with a ﬂow rate of 0.75 ml/min.
The UV detector was set at 309 nm for etamsylate and 254 for
the internal standard (IS; allopurinol). The detector was pro-
grammed at 254 nm for 6.8 min and at 309 nm for the subse-
quent 1.2 min to measure etamsylate and IS, respectively, and
the peak areas were calculated using the data analysis program
Class-VP (Shimadzu Scientiﬁc Instruments, Kyoto, Japan).
2.4. Standard solutions
For the construction of calibration curves, drug stock solution
(500 lg/ml) was prepared by dissolving etamsylate powder in
methanol. The stock solution was further diluted in methanol
to prepare seven working solutions of etamsylate with concen-
trations of (200, 100, 50, 20, 10, 5 and 25 lg/ml) for spiking hu-
man plasma samples. Standard solutions were stored at
+4 C. The internal standard stock solution was prepared
by dissolving allopurinol powder in methanol to give concen-
tration of 30 lg/ml which is used as the IS for etamsylate anal-
ysis in human plasma.
2.5. Plasma sample preparation
The calibration standards of etamsylate were prepared by
transferring 25 ll from each working solution of etamsylate
and IS to a set of test tubes. The solvent was evaporated,
and 0.25 ml of blank plasma was added to each tube to form
a set of calibration standards with concentrations of 0.25,
0.5, 1, 2, 5, 10 and 20 lg/ml. The sample was vortexed, and
then 0.25 ml of 6% trichloroacetic acid was added, shaken
for one min, and centrifuged at 3000 rpm for 7 minutes. The
supernatant was separated and 25 ll was injected into the
HPLC.2.6. Assay validation
The method was validated with respect to linearity, selectivity,
precision, accuracy, speciﬁcity, and stability.
2.6.1. Linearity
The linearity of the calibration curve in human plasma was
conﬁrmed by plotting the peak-area ratios of (drug/IS) versus
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linear regression analysis.2.6.2. Selectivity
The retention time of the drug in the standard curve of spiked
plasma blanks and the study samples were compared to deﬁne
any endogenous materials and/or degradation peaks appeared
at the same retention time of etamsylate and IS in the HPLC
chromatograms.
2.6.3. Precision and accuracy
The precision of the assay was measured by the within day and
between-day percent coefﬁcient of variation (%CV) over the
concentration range of calibration curve of etamsylate in plas-
ma during the course of validation. Within day precision of the
assay was determined by the analysis of three replicates of the
calibration curve in the same day. The between-day precision
was evaluated by the analysis of six different calibration curves
in six different days during the study period. The %CV of the
measured concentrations was used to determine the precision
of the assay. The accuracy of the assay was deﬁned as the abso-
lute mean value of the ratio of the back calculated mean values
of the unknown samples and their nominal values, expressed
as a percentage. The measured concentrations of the within
day and between-day analysis were compared to the nominal
concentrations to determine the accuracy of the assay.
2.6.4. Speciﬁcity
Three quality control samples (QC) at concentrations of 0.5,
2.0 and 10.0 lg/ml, (LLOQ, MQC and HQC) were prepared
as unknown samples. The concentration in each QC sample
was determined from the calibration curve and the calculated
concentration was compared with the nominal concentration.
Intra-day precision and accuracy were evaluated by analyzing
each QC sample six times on the same day, while inter-day pre-
cision and accuracy were evaluated by analyzing each QC sam-
ple in 6 consecutive days.
2.6.5. Stability
The stability of the drug at room temperature was determined
by preparing three different plasma samples for each drug con-
centration then the samples were injected immediately into the
HPLC. The samples were kept at room temperature and were
injected again after 24 h. The concentrations measured at time
zero and after 24 h were compared to determine any changes in
the concentrations with time. The 24 h period was selected be-
cause it is the maximum time between the preparation of sam-
ples and injection into the HPLC. The stability of the drug in
frozen plasma was investigated by the analysis of the study
samples obtained from three volunteers twice. The ﬁrst analy-
sis was performed at the beginning of the study and the second
analysis was performed at the end of the study. The samples
were stored at 80 C between the analyses.
2.7. Clinical pharmacokinetic study
2.7.1. Study design
This study was monitored in accordance with the International
Conference of Harmonisation (ICH) guidance on general con-
siderations for clinical trials.2.7.2. Study population
Twenty-four male Egyptian volunteers with a mean ± SD age
of 22.70 ± 4.090 years (range, 18–32 years) and mean ± SD
weight of 69.37 ± 7.037 kg (range, 58–82 kg) were chosen to
participate in the present study. All subjects completed an
acceptable medical history, medication history, physical exam-
ination, an electrocardiogram, blood pressure, screens for
HIV-1 and -2 antibodies and hepatitis B surface antigen, and
a urine drug screen prior to study initiation. Selected routine
clinical laboratory measurements were performed during
screening. Exclusion criteria were: (1) treatment with any
known enzyme-inducing/inhibiting agents within 30 days prior
to the start of the study and throughout the study; (2) suscep-
tibility to allergic reactions to drugs; (3) any prior surgery of
the gastrointestinal tract that may interfere with drug absorp-
tion. Upon completion of study, the physical examination and
clinical laboratory measurements were repeated. The subjects
were instructed to abstain from taking any medication for
1 week prior to and during the study period. All enrolled vol-
unteers were healthy, and none of the participants showed any
signs of adverse drug reactions during or after completion of
the study. Informed consent was obtained from the subjects
after explaining the nature and purpose of the study. The study
protocol was approved by the ethics committee of Tanta Uni-
versity Hospital, Egypt.
2.7.3. Dosing schedule
In the morning of study, after an overnight fasting (10 h), vol-
unteers received a single dose of one Dicynone tablet (500 mg
etamesylate) followed by 200 ml of water. The volunteers were
continuously monitored by a qualiﬁed staff throughout the
conﬁnement period of study. Food and drinks were withheld
for at least 2 h after dosing. Water intake was allowed after
2 h of dose; water, lunch and dinner were given to all volun-
teers according to a time schedule. All subjects were asked to
abstain from the consumption of fruit juices during the study
period.
2.7.4. Collection of blood samples
Venous blood (5 ml) was taken from the forearm by vein punc-
ture prior to (0 h) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6,
8, 10, 12, 24 and 48 h after each drug intake. The blood sam-
ples were drawn into 10 ml heparinized tubes and plasma was
directly separated by centrifugation at 3000 rpm for 10 min,
transferred into polypropylene plastic tubes, and stored at
80 C until assay.
2.7.5. Monitoring of adverse effects
Throughout the study, the subjects were questioned and exam-
ined for the presence of adverse drug reactions. All the partic-
ipated volunteers did not show any sign of adverse drug
reactions during or after completing the study.
2.7.6. Determination of pharmacokinetic parameters
The developed HPLC method was used to investigate the plas-
ma concentration–time proﬁle of etamsylate after administra-
tion of 500 mg tablet. Study samples were treated as the
calibration standards. A non-compartmental model was used
to determine the pharmacokinetic parameters of etamsylate.
The elimination rate constant (Ke) was estimated by least
Figure 3 Representative chromatograms for blank plasma
sample and blank plasma spiked with etamsylate to produce a
drug concentration of 10 lg/mL and the internal standard (IS).
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the terminal log-linear region of the curves. Half-life (t1/2) was
calculated as 0.693 divided by Ke. The AUC from zero to the
last quantiﬁable plasma concentration (AUC0–t) was calcu-
lated using the linear trapezoidal rule. The AUC from zero
to inﬁnity (AUC0–1) was calculated as AUC0-1
(AUC0–t + C/Ke), where C is the last measured concentration
(Gilbaldi and Perrier, 1982; Hedaya, 2007). Cmax and tmax were
obtained directly from the individual plasma concentration–
time curve. The apparent total clearance (Cl/F) was calculated
as oral clearance (CL/F) = Dose/AUC0–1 while the apparent
volume of distribution (Vd/F) was estimated as Oral Clear-
ance/K relative to the bioavailability (F) of etamsylate. Area
under the ﬁrst moment curve (AUMC) was calculated by trap-
ezoidal integration and extrapolation to inﬁnity. Mean resi-
dence time (MRT) was calculated as the ratio (AUMC)/
(AUC0–1) (Gilbaldi and Perrier, 1982; Hedaya, 2007).
3. Results and discussions
3.1. Conditions of chromatography
Method development was focused on the development and
optimization of suitable sample preparation and chromato-
graphic separation. Several tests were performed for optimiz-
ing the components of mobile phase in order to achieve
good chromatographic peak shape and resolution. Good sep-
aration of etamsylate and IS with short run times were ob-
tained using a mobile phase system of 20 mM sodium
dihydrogen phosphate-2 hydrate (pH was adjusted to 3.5 by
phosphoric acid) and acetonitrile at a ratio of 95:5 v/v; at
0.75 ml/min ﬂow rate. The UV detector was programed at
309 nm for 6.8 min and at 254 nm for the subsequent 1.2 min
to measure etamsylate and IS, respectively at retention times
that were quite short for IS and etamsylate at 6.3 ± 0.09
and 7.2 ± 0.1 minutes, respectively. For plasma samples,
deproteinization with 6% trichloroacetic was adopted, which
was simple and fast resulting in sharp and symmetrical peaks.y = 0.139x - 0.0102
R 2 = 0.9999
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Figure 2 Calibration curve of etamsylate in spiked plasma
(mean ± S.D.; n= 8).3.2. Validation of HPLC method
3.2.1. Linearity
Calibration curves were linear with a correlation coefﬁcient
R2 > 0.999 throughout the course of the assay (20–0.25 lg/
ml) for etamsylate as shown in Fig. 2.
3.2.2. Selectivity
Typical chromatograms obtained from blank human plasma
and the plasma spiked with etamsylate and IS are shown in
Fig. 3, which indicates that no peaks for any endogenous com-
pound appeared at the same retention time for etamsylate and
IS.
3.2.3. Precision and accuracy
Precision and accuracy results demonstrated good precision
and accuracy over the concentration range selected. Intra-
and inter-day precision and accuracy for etamsylate from plas-
ma data are listed in Table 1. The within day and between-day
%CV were always within ±10% in the entire range of the cal-
ibration curve. The within day %CV ranged from 3.9% to
10.2%, whereas, the between-day %CV ranged from 3.1%
to 8.7%. The intra-day accuracy ranged between 99.0% and
109.4%, whereas the inter-day accuracy ranged between
98.4% and 108.2%.
3.2.4. Speciﬁcity
Intra- and inter-day precision and accuracy for the three qual-
ity control samples in human plasma were evaluated and de-
picted in Table 2.
3.2.5. Stability
Short-term stability showed that etamsylate is stable in plasma
for at least 24 hrs at room temperature. The difference in the
drug concentration in all samples obtained from volunteers
in the two analyses performed at the beginning and at the
end of the study was always less than 10% in each sample in
frozen plasma stored at 80 C during the study period, indi-
cating the stability of etamsylate in frozen plasma.
Table 1 The day-to-day (intra-day) and between-days (inter day) precision and accuracy of the assay.
Nominal concentration (lg/ml) Day-to-day (intra-day)a Between-days (inter-day)b
Concentration
found (lg/ml)
(mean ± S.D)
Precision
(%)
Accuracy
(%)
Concentration
found (lg/ml)
(mean ± S.D)
Precision
(%)
Accuracy
(%)
20 20.9 ± 1.21 5.77 104.8 20.09 ± 1.27 6.32 100.4
10 10.2 ± 0.40 3.91 102.3 10.14 ± 0.32 3.15 101.4
5 5.10 ± 0.32 6.38 102.1 5.185 ± 0.40 7.81 103.7
2 1.98 ± 0.20 10.2 99.00 1.97 ± 0.08 4.41 98.5
1 1.08 ± 0.07 6.67 109.4 0.984 ± 0.04 4.33 98.4
0.5 0.50 ± 0.03 6.09 101.8 0.541 ± 0.04 8.53 108.2
0.25 0.27 ± 0.01 4.44 108.0 0.251 ± 0.02 8.76 100.4
a n= 3 for each concentration.
b n= 6 for each concentration.
Table 2 Quality control samples.
Nominal concentration (lg/ml) Concentration found (lg/ml; mean ± S.D.) Precision (%) Accuracy (%)
10 9.84 ± 0.99 10.0 98.4
2.0 1.89 ± 0.13 6.87 94.5
0.5 0.53 ± 0.05 9.39 106.4
0
1
2
3
4
5
6
7
8
0 10 20 30 40 50
Time (hr)
Et
am
sy
la
te
 
pl
as
m
a 
co
n
c 
(µg
/m
l)
Figure 4 Mean plasma concentrations of etamsylate in 24
healthy volunteers after a single oral dose administration of one
Dicynone tablet (500 mg etamsylate) (mean ± standard error).
Table 3 Pharmacokinetic parameters of etamsylate after a
single oral dose administration of one Dicynone (500 mg
etamsylate) to 24 healthy Egyptian male volunteers.
Parameters Etamsylate
Mean %CV
Cmax (lg/ml) 8.05 30.3
tmax (h) 5.02 27.7
AUC0 ﬁ t (lg h/ml) 78.7 32.6
AUC0 ﬁ 1 (lg h/ml) 84.8 31.0
t1/2 (h) 9.4 34.9
MRT (h) 15.7 14.8
Cl/F (ml/min) 6470.5 25.1
Vd/F (ml) 86629.7 23.4
Cmax, peak plasma concentration; tmax, time to reach peak plasma
concentration; AUC0–1, area under the concentration–time curve
from zero to inﬁnity; AUC0–t, area under the concentration–time
curve from zero to the last measurable plasma concentration;
AUCt–1, area under the concentration–time curve from the last
measurable plasma concentration to inﬁnity; t1/2, elimination half-
life; MRT, mean residence time; Cl/F, clearance; Vd/F, volume of
distribution.
A new and simple HPLC method for determination of etamsylate in human plasma 409The described analytical method was proven to be sensitive
and accurate for the determination of etamsylate in plasma
where, all validation parameters were within the acceptable
limits which indicate the suitability of the developed analytical
method for pharmacokinetic study.
3.3. Pharmacokinetic results
The developed method was used for the pharmacokinetic study
of etamsylate in 24 healthy Egyptian volunteers. After oral
administration of 500 mg etamsylate, the concentration versus
time proﬁle of etamsylate was constructed. The mean plasma
concentration–time curve of etamsylate is shown in Fig. 4.The results showed that the method was reliable and adequate
to provide pharmacokinetic concentration–time proﬁle for a
dose of etamsylate of 500 mg tablet. Etamsylate was readily
absorbed from the gastrointestinal tract and it was measurable
at the ﬁrst sampling time (0.25 h) in almost all volunteers. The
major pharmacokinetic parameters of etamsylate were listed in
Table 3.
4. Conclusions
A new and simple HPLC method for the determination of
etamsylate in human plasma was developed and validated over
410 S.A. Helmy, H.M. El Bedaiwythe concentration range from 0.25–20 lg/ml. The method has
been successfully applied to the pharmacokinetic study of
etamsylate in Egyptian healthy male volunteers and satisfac-
tory results were obtained, which demonstrates that the
method is reproducible, sensitive and reliable. Owing to great
therapeutical importance of etamsylate and widespread use;
this work is considered as a primary step in preparing con-
trolled release preparations in the future.
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